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Abstract
Background: Array comparative genomic hybridization (aCGH) is recommended as a first-tier genetic test for
children with autism spectrum disorder (ASD). However, interpretation of results can often be challenging partly
due to the fact that copy number variants (CNVs) in non-European ASD patients are not well studied. To address
this literature gap, we report the CNV findings in a cohort of Chinese children with ASD.
Methods: DNA samples were obtained from 258 Chinese ASD patients recruited from a child assessment center
between January 2011 and August 2014. aCGH was performed using NimbleGen-CGX-135k or Agilent-CGX 60k
oligonucleotide array. Results were classified based on existing guidelines and literature.
Results: Ten pathogenic CNVs and one likely pathogenic CNV were found in nine patients, with an overall diagnostic
yield of 3.5%. A 138 kb duplication involving 3′ exons of DPP10 (arr[GRCh37] 2q14.1(116534689_116672358)x3),
reported to be associated with ASD, was identified in one patient (0.39%). The same CNV was reported as variant of
uncertain significance (VUS) in DECIPHER database. Multiple individuals of typical development carrying a similar
duplication were identified among our ancestry-matched control with a frequency of 6/653 (0.92%) as well as from
literature and genomic databases.
Conclusions: The DPP10 duplication is likely a benign CNV polymorphism enriched in Southern Chinese with
a population frequency of ~1%. This highlights the importance of using ancestry-matched controls in interpretation of
aCGH findings.
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Background
Autism spectrum disorders (ASD) refer to conditions
characterized by impairment in social interaction and
social communication, as well as restricted or repetitive
behavior, interests, and activities [1]. ASD is well known
to have a genetic basis, in particular, studies from the re-
cent decade have shown that rare and fully penetrant
copy number variations (CNVs) explain approximately
5–10% of the disorder depending on the cohort exam-
ined and the platform used for analysis [2], a yield that
is substantially higher than conventional karyotyping [3].
Therefore, the latest guidelines by the International
Standards for Cytogenomic Arrays (ISCA) Consortium
has recommended chromosomal microarray as the first
line investigation for children with ASD and various de-
velopmental disorders [4].
The interpretation of CNV pathogenicity is challen-
ging and complicated by various factors. It has been
shown that the diagnostic yield of array comparative
genomic hybridization (aCGH) in a fixed cohort of
pediatric patients with intellectual disability (ID) have in-
creased from 19 to 31% in 2 years. Reasons for the re-
classification of CNVs include emergence of new
literature on known genes, discovery of new candidate
genes, refinement of information, and remapping of gene
location [5]. On the contrary, because of the rare nature
of conditions encountered in clinical genetics, ascertain-
ment bias due to small sample sizes or ancestry-related
differences in CNV carrier frequency may occur [6]. In a
recent study, Manrai et al. pointed out that the possibil-
ity of ruling out the pathogenicity of a population-
enriched benign variant depends on the representation
of specific population in the overall sample and that five
variants previously classified as pathogenic for hyper-
trophic cardiomyopathy were misclassified because they
were much more prevalent in African Americans, which
were under-represented in previous studies [7]. Ascer-
tainment bias is particularly challenging outside North
America and Europe since most studies on CNV are fo-
cused on patients of European ancestry. Previous studies
in general Asian populations have also shown substantial
differences in terms of the location and frequency of
CNVs across the genome [8].
CNV studies of ASD in Chinese patients have mostly
been limited to case reports or candidate gene single nu-
cleotide polymorphisms (SNPs) based on findings in
ASD patients of European ancestry [9]. Using research
array platforms and bioinformatics pipelines, Gazzellone
et al. [10] and Yin et al. [11] reported on 104 and 335
ASD probands from Harbin of northern China and
Taiwan, respectively. We examined the characteristics of
CNVs in a southern Chinese cohort with clinically diag-
nosed ASD to address this knowledge gap. A clinical
aCGH platform was used for the analysis. This gives the
advantages of yielding clinically relevant results and
utilization of comparable controls from our diagnostic
laboratory service.
Methods
Patient recruitment
Patients diagnosed with ASD from the Department of
Paediatrics and Adolescent Medicine, the University of
Hong Kong, in the period from January 2011 to August
2014 were enrolled into the study. Diagnosis of ASD
was made by developmental pediatrician or clinical
psychologist using the Diagnostic and Statistical
Manual of Mental Disorders, fourth edition, text revi-
sion (DSM IV-TR) or fifth edition (DSM-V). In difficult
cases, tools such as Childhood Autism Rating Scale
(CARS), Checklist for Autism in Toddlers (CHAT-23
modified) [12], Autism Diagnostic Interview Revised
(ADIR), and Autism Diagnostic Observation Schedule
(ADOS) were used. For the genetic evaluation, we
followed the suggestion by Miller et al [4]. We offered
aCGH to patients with unexplained ASD as the first-
tier testing after review by a clinical geneticist.
Clinically recognizable syndromic conditions would be
confirmed with appropriate genetic test targeted to that
specific condition, and aCGH would only be offered if
the targeted testing showed negative results. We re-
cruited 288 patients with ASD, and DNA was obtained
from these individuals. Subsequently, DNA was also
obtained from their parents in the post-aCGH genetic
counseling session. The recruitment process did not
discriminate between children of various ethnicities but
our analysis focused on only 258 patients of self-
reported Chinese ethnicity. Some of the patients
reported in this study were also included in a previous
publication describing the impact of aCGH on clinical
management [13]. However, the current manuscript
focuses only on patients with ASD and includes 116
additional ASD patients.
Genotyping and variant calling
Out of the 288 patients, aCGH of 255 (88.5%) were done
using Nimblegen CGX-135k oligonucleotide array, and
33 (11.5%) were done using Agilent-CGX 60k oligo-
nucleotide array. Array processing and analysis was
performed in the diagnostic laboratory of Tsan Yuk
Hospital (TYH), which offers both prenatal and postna-
tal aCGH testing for patients in Hong Kong. Details of
the testing methodology, variant calling, and interpret-
ation have been previously reported [13].
Detected CNVs were systematically evaluated for their
clinical significance by comparing the CNVs to informa-
tion in the Signature Genomics’ proprietary Genoglyphix
Chromosome Aberration Database (Signature Genomics,
Spokane, WA, USA), internal laboratory database at
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TYH, and public databases (Database of Genomic
Variant (DGV), ISCA Database, Children Hospital of
Philadelphia database (CHOP), and Database of
Chromosomal Imbalance and Phenotype in Humans
using Ensembl Resources (DECIPHER)). Categorization
of CNVs was based on available phenotypes and com-
parison of phenotypes with genes in the region of copy
gain or loss. This was done through searching Online
Mendelian Inheritance in Man (OMIM), PubMed,
RefSeq, and the University of California Santa Cruz
(UCSC) genome browser. CNVs were classified to (a)
pathogenic, (b) variant of uncertain clinical significance
(VUS) of likely pathogenic, (c) VUS of likely benign, (d)
VUS with no subclassification, or (e) benign according
to the 2013 American College of Medical Genetics &
Genomics (ACMG) practice guideline [14]. Only patho-
genic and likely pathogenic CNVs were regarded as clin-
ically significant. TYH possesses an internal control
database of 653 individuals of Chinese ethnicity with
typical development and insignificant medical his-
tory determined by a self-administered question-
naire. Majority of the controls are parental samples
(n = 554) that were primarily collected for prenatal
diagnostic interpretation.
Validation of CNVs
CNVs involving the 3′ exons of DPP10 in the current
study were confirmed by digital PCR, using the
QuantStudioTM 3D Digital PCR System platform and
ProFlex PCR System (Life Technologies, CA). Taqman
copy-number primer-probe assay was designed using
GeneAssistTM Copy Number Assay workflow builder.
The reaction mix was loaded onto a QuantStudioTM 3D
Digital PCR 20K Chip using an automatic chip loader
according to the manufacturer’s protocol. The chips
underwent thermocycling on the ProFlex PCR System
with the default conditions suggested by the primer-
probe assay. After PCR, chip images were analyzed using
QuantStudioTM 3D instrument.
Quantitative real-time PCR (qPCR) was performed to
more accurately delineate the breakpoints of the DPP10
CNVs in our DNA samples. Ten primer assays, five at
the proximal site and five at the distal site, were de-
signed followed by qPCR using QuantiNova SYBR Green
PCR Kit (Qiagen, Germany) on a 7900 Fast Real-time
PCR System (Applied Biosystems, MA). Cycle threshold
(Ct) value was called by the software RQ manager v1.2,
and the relative copy number of the target assay was de-
termined using comparative Ct method.
Results
Out of the 258 Chinese patients recruited, 215 were
male and 43 were female, with a male to female ratio
5:1. Their age ranged from 1.5 to 25 years old. As
mentioned above, our analysis focused on the 258
patients of self-reported Chinese ancestry. Of these, par-
ental blood samples were obtained from both parents in
24 cases, from mothers only in three cases, and from a
father only in one case. Ten patients were siblings from
five families, and the rest of the patients were unrelated.
We did not identify many known CNVs previously im-
plicated in ASD. For example, there were no PTCHD1-
related CNVs, and none overlapping the loci of 22q11.2,
1q21, 5q15.2, 7q11, 15q13, or 17p11.2 [15, 16]. Never-
theless, patient 2 did harbor a distal 16p11.2 deletion. In
addition, there were also CNVs found in the regions of
16p13.3 and 6q26 reported by Gazzellone et al. [10] and
Yin et al. [11], respectively.
Clinically significant CNVs
All identified CNVs were classified according to the
ACMG Guidelines [14, 17]. Ten pathogenic CNVs and
one likely pathogenic CNV were found in nine patients,
resulting in a diagnostic yield of 3.5% (9/258) (Table 1).
We detected a total of 52 VUS in 43 patients (16.7%). Of
these, 2 CNVs overlap with VUS and 6 had partial over-
lap with those reported as pathogenic CNVs in ISCA
database [18], while 21 overlap with those reported as
VUS in DECIPHER [19]. A summary table of all VUS is
shown (see Additional file 1).
Patient 1 presented with high-functioning autism at
the age of 4 years. There was no associated dysmorph-
ism or physical anomaly. His parents were non-
consanguineous, and there was a strong family history of
high-achieving paternal male relatives with weak social
skills. He was found to have two CNVs—a paternally
inherited 0.36 Mb deletion at 7q31.1 classified as a VUS,
as well as a de novo pathogenic 6.98 Mb deletion
encompassing 15q25.2-26.1. The smaller 7q31.1 deletion
encompasses IMMP2L, a gene whose SNPs were shown
to be associated with ASD in a predominantly Caucasian
study [20] but not in another study with northeastern
Han Chinese [21]. On the other hand, the larger
15q25.2-26.1 deletion involved up to 40 OMIM genes,
and the deletion is in close proximity with the more
distal 15q26 region which is associated with neurobe-
havioral phenotype including ASD, attention deficit
hyperactivity disorder (ADHD), learning difficulty, and
hearing impairment [22].
Patient 2 presented with global developmental delay
(GDD) and ASD at 18 months of age, and subsequently
demonstrated satisfactory catch up in developmental
milestones and autistic features. He had mildly elongated
and expressionless face with open mouth appearance
and downturned angles of mouth. His parents were non-
consanguineous. Apart from the presence of specific lan-
guage impairment in his elder brother, there was no
family history of neuropsychiatric illness. He was found
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to have a de novo 0.56 Mb distal 16p11.2 microdeletion
which not only explains his neurodevelopmental pheno-
type, but is also associated with obesity [23]. Identifica-
tion of the deletion facilitated the need to conduct
regular weight surveillance, highlighting the importance
of genetic testing in anticipatory management of gen-
omic conditions. Despite the positive history of specific
language impairment, his brother was tested negative for
the 16p11.2 deletion, underscoring the genetic hetero-
geneity of ASD and that in ~70% of families with mul-
tiple affected siblings, the affected children might carry
different ASD-relevant mutations or CNVs [24].
Patient 3 presented at 32 months of age with GDD
and ASD, in association with soft dysmorphic features
including telecanthus, small low-set ears with slightly
thickened helices, and slightly shortened forearms. Her
height was normal at presentation but fell from the 25th
to 3rd percentile within the subsequent year. Further
questioning revealed that there was also antenatal history
of short long bones, which was commented to be normal
post-delivery. Her parents were non-consanguineous and
there was no family history of neurodevelopmental disor-
ders. She is now studying in a school for children with mild
ID. Her microarray showed a pathogenic Xp22.33 de-
letion measuring 3.72 Mb that encompassed both
ASMT and SHOX, which can explain the clinical fea-
tures of the patient. The mother was tested negative
for the CNV while paternal information was not
available. The ASMT gene was shown to be associated
with social impairment and autistic traits [25],
whereas the SHOX gene is known to be associated
with short stature. Together, the two genes explained
her overall clinical picture. The findings prompted
further radiographic assessment, which showed mild
Madelung deformity of her forearms, reaffirming the
microarray findings. Despite being eligible for receiv-
ing growth hormone therapy under public healthcare
funding, her parents opted not for treatment as they
were satisfied with the overall growth of the child.
Again, this patient revealed the importance of under-
standing the underlying molecular defects prompting
targeted surveillance of possible complications. Her
developmental progress was reassessed at 5 years of
age, showing persistence of ASD with mild ID. She is
scheduled to enter school for children with mild ID.
Patient 4 presented with GDD at 18 months and was
diagnosed to have ASD in early childhood. On subse-
quent visits he was also noted to have hyperactivity fea-
tures. His intellectual ability caught up gradually with
above-average academic performance in mainstream
school. His parents were non-consanguineous, and apart
from his twin brother who was diagnosed with develop-
mental language delay, there was no family history of
neurodevelopmental disorder. For both the patient and
his twin brother, aCGH showed XXY, which was indica-
tive of Klinefelter syndrome. The association between
Klinefelter syndrome and ASD has been previously
described [26]. He was also followed up by endocrinolo-
gists for potential complications of the syndrome.
Patient 5 presented with language delay with mild aut-
istic features at 18 months. Further assessment at
26 months confirmed the diagnosis of ASD. At 6 years
3 months, assessment revealed borderline ID with
persistence of ASD features. Her parents were non-
consanguineous, and there was no family history of neu-
rodevelopmental disorder. She was found to have 1q44
deletion of 2.40 Mb as well as 8q24.22q24.3 duplication
of 10.76 Mb, which was associated with GDD in the
DECIPHER database and implicated in the autism endo-
phenotype of social responsiveness in genome-wide
quantitative linkage analyses respectively [27]. Such re-
sults prompted further testing with karyotype and fluor-
escence in situ hybridization (FISH), which confirmed
that the changes were due to an unbalanced transloca-
tion. Parental information was not available.
Patient 6 presented with language delay, ASD at
22 months. There was no dysmorphic feature except the
presence of penile hypospadias requiring surgical repair,
and his cognitive function was normal. His parents were
non-consanguineous and there was no family history of
neurodevelopmental disorder. He was found to have a
de novo 0.47 Mb duplication of likely pathogenic as it
involved the PARK2 gene. The gene encodes for an ubi-
quitin protein ligase, which was first discovered in early
onset Parkinson disease with autosomal recessive muta-
tions [28] and later found to be associated with CNVs in
schizophrenia [29] and neurodevelopmental disorders
including ADHD [30] and ASD [15]. CNV involving this
region was the focus of a previous publication from Yin
et al, where it was found in 4 out of 335 ASD patients of
Han Chinese descent [11].
Both patients 7 and 8 were diagnosed with ASD but
with different neurodevelopmental outcome. Patient 7
had a history of suspected neonatal seizure in association
with a small subdural hematoma possibly secondary to
traumatic delivery. Subsequent magnetic resonance im-
aging (MRI) of the brain was normal. He presented with
language delay and autistic features at 17 months and was
diagnosed with ASD at 23 months. At the age of 5, cogni-
tive assessment revealed an average intelligence quotient
with signs of dyslexia. No major challenging behavior was
detected. On the other hand, patient 8 presented during
preschool years with GDD and autistic features and was
subsequently diagnosed to have ASD as well as moderate
ID. He also had adolescent-onset epilepsy requiring long-
term use of sodium valproate. MRI of the brain showed a
static arachnoid cyst at the left anterior middle cranial
fossa which was managed conservatively. However, he
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developed significant behavioral difficulties at adolescence
requiring intensive management by the psychiatrists. Both
patients came from families with non-consanguineous
parents and without family history of neurodevelopmental
disorders. Their aCGH results both showed 1.16 Mb du-
plications at 16p13.11. Despite previous concerns regard-
ing the possibility of this CNV being a benign variant [31],
further studies have provided evidence of its pathogenicity
in multiple neuropsychiatric conditions including ASD,
ADHD, ID, and schizophrenia [32–34]. Epilepsy has
also been reported in association with 16p13.11 dupli-
cation [34].
Patient 9 presented with impaired social interaction at
29 months and was diagnosed with ASD. There was no
associated physical anomaly, and his cognitive function
was normal. His parents were non-consanguineous, and
there was no family history of neurodevelopmental dis-
orders. He was found to have two consecutive
duplication in mosaic pattern, 11q12.1q12.2 (5.55 Mb)
and 11p11.2 (0.29 Mb), spanning across the centromere.
The result was suggestive of a marker chromosome,
which was later confirmed by the karyotype mos
47,XY,+mar[8]/46,XY[52]. No case was previously re-
ported in the literature but there was one entry (Variant
ID: NSSV582454) in the ISCA database [35] with similar
duplication size of 3.67 Mb, presenting as GDD and
delayed speech and language development.
DPP10 duplication—a CNV polymorphism enriched in
Chinese population
A Chinese-enriched CNV polymorphism was identified
at the 3′ exons of DPP10, a gene previously speculated
to have a role in ASD [36, 37]. DPP10 encodes for
dipeptidyl peptidase like 10. DPP10 has at least five tran-
script variants, and the primary transcript has 26 exons.
The gene was previously implicated in ASD susceptibil-
ity in at least two large independent studies (See Fig. 1).
Within our cohort, we identified only one 0.14 Mb du-
plication arr[GRCh37] 2q14.1(116534689_116672358)x3
overlapping exons 14 to 26 of DPP10 (NM_020868.3) in
a 17-year-old patient (patient 10). Other than ASD, he
also had catatonia and mild ID. Parental aCGH testing
was declined (see Fig. 1).
This CNV involving DPP10 has been reported as a
VUS (ID: 287659) in DECIPHER with 50% reciprocal
overlap. Two studies have reported CNVs associated
with DPP10 before. Girirajan et al. [37] identified five
patients with duplications among 2588 cases, three of
whom had more than 50% reciprocal overlap with pa-
tient 10, and the remaining two only partially overlap.
On the other hand, Marshall et al. [36] identified two
CNVs (one deletion and one duplication) in 427 unre-
lated ASD probands, both of which did not overlap with
the CNV identified in our cohort. The CNVs associated
with DPP10 reported in the above two studies are listed
in Additional file 2. No such duplication was found in
any of the controls from the above projects, which com-
prised of 500 individuals from the German PopGen pro-
ject, 1152 from Canada, 207 from the National Institute
of Mental Health (NIMH) control cohort with exclu-
sively European origins, and 373 individuals from
ClinSeq comprising of more than 90% Caucasians [38].
Despite these findings, within the local laboratory
database, we found similar duplications in 17 other pa-
tients (3 postnatal cases and 14 prenatal cases). The clin-
ical indications were heterogeneous, and recruitment
and follow up of these patients were not done systemat-
ically and therefore would be subjected to different
ascertainment bias. Nevertheless, as far as we can ascer-
tain, none of these patients had evidence of ASD.
To describe the details of these patients further,
among the three patients found in the postnatal cohort
(n = 3/441); there was one patient with mild develop-
mental delay, one with short stature but normal devel-
opment, and one with dysmorphic features, hypotonia
during neonatal period, and subsequently normal devel-
opment. Non-ASD individuals with the CNV overlap-
ping DPP10 are listed (see Additional file 3). All of the
above three patients had DPP10 duplication. In the pre-
natal cohort (n = 14/1150) on the other hand, referral
indications were as follows: (i) stillbirth (n = 1), (ii) ab-
normal antenatal ultrasound (n = 6), (iii) abnormal an-
euploidy screening (n = 5), of which three were later
confirmed with trisomy 21, and (iv) previous children
with aneuploidy (n = 2). In total, 13 DPP10 duplications
and one deletion (n = 14) of the same size and genomic
location were identified in the prenatal group. The
clinical outcomes of these 14 pregnancies included one
stillbirth and three terminations of pregnancies, which
included two of the three cases with both trisomy 21
and DPP10 duplication. The other ten were liveborns
(71.4%), and their development was followed up routinely
in the Maternal and Child Health Centre. Besides
the remaining child with trisomy 21 in addition to
the DPP10 duplication, one additional child was
found to have GDD and one other has mild atten-
tion problem (7.1%).
In order to estimate the prevalence of the DPP10 dupli-
cation in Hong Kong, we examined the internal control
database of TYH, which consisted of 653 Chinese of typ-
ical development, and their DNA samples were genotyped
and analyzed using the same methods as our positive
cases. Six out of 653 individuals were identified to have
the similar DPP10 duplications (0.92%). When comparing
the prevalence of DPP10 duplications in ASD cases (1/
258) and controls (6/653), the p value did not infer statis-
tical significance (p = 0.68, two-tailed Fisher’s test) to sug-
gest any causative nature of DPP10 duplication in ASD.
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Molecularly, we validated and mapped the break-
points in 24 different samples carrying the DPP10
duplication (and deletion) by qPCR and found that both
the 5′ and 3′ ends consistently map to the same regions.
By the same method of qPCR, the breakpoints of the CNV
were narrowed down further from hg[19]chr2:116524182-
116529245 proximally to hg[19]chr2:116672358-116677229
distally.
The ancestry-related difference in the background
prevalence of DPP10 duplication was further studied by
literature and database search. Park et al. [8] sought to
identify common Asian CNVs. Interestingly, in their
study, one DPP10 duplication of size and location com-
parable to our patient was found in one out of ten Han
Chinese subjects but not in subjects of Japanese or
Korean descent. Extensive search of regional databases,
various studies [39–44] extracted from DGV [45], the
cohort of Itsara et al. [46], and the Singapore Prospective
Study Program (SP2) [47, 48] was performed. Seventy-
two individuals with typical development and CNVs
containing DPP10 of at least 50% physical overlap the
one identified in our ASD cohort were identified. Indi-
viduals with the CNV are listed (see Additional file 4).
Within the SP2 cohort, where ethnicity is available, the
duplication was found in 14/2857 (0.49%) individuals of
Chinese origin.
Discussion
This study adds to the growing number of CNV studies
in ASD in Chinese and is to our knowledge the third
study with over a hundred patients. The first two studies
were by Gazzellone et al. [10] on 104 Chinese from
Harbin and Yin et al. who reported the CNV findings in
a clinical ASD cohort of 335 Han Chinese (with a repli-
cation cohort of 301 ASD individuals) from Taiwan [11].
Fig. 1 Genomic browser figure showing CNVs overlapping DPP10 in various databases. This figure was modified from the USCS genome browser
(https://genome.ucsc.edu). Different isoforms of CNVs containing DPP10 reported in literature, as well as CNVs from relevant databases of at least
50% physical overlap to the one identified in our ASD cohort are included. Red and blue bars represent deletions and duplications, respectively.
Subjects from the TYH database are represented at the top of the figure; ASD subjects reported by Girirajan et al. and Marshall et al. are represented in
the middle part of the figure. Control subjects reported in Database of Genomic Variants (DGV) study are represented at the lower part of the figure.
Case numbers are consistent throughout the article, table, and supplemented documents
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Gazzellone et al. identified at least one de novo rare
CNV in 8.6% of his cohort whereas Yin et al. found sev-
eral well-known ASD-associated CNVs from other ASD
populations (e.g., 1q21.1, 15q11.21-13.1, 15q13.3, 16p11.2,
22q11.2, 22q13.33) in 5.1% Taiwan Chinese with ASD.
The diagnostic yield of our cohort in Hong Kong is 3.5%
but direct comparison is difficult as our study is the only
one among the three that uses a clinical aCGH platform
and reports only pathogenic/likely pathogenic CNVs using
stringent clinical laboratory criteria [13]. We did not iden-
tify many known ASD-associated CNVs, perhaps due to
the limited sample size of the cohort.
Although there were some overlap of our findings with
these studies, such as 16p11.2 deletion and CNV involv-
ing PARK2, the results of these three studies substantiate
the extensive genetic heterogeneity that is inherent to
ASD even within the Chinese population. Further work
in this ethnic group may identify new population-
enriched variants that contribute to ASD, e.g., PARK2
locus from Yin et al. On the other hand, identification of
ethnic specific loci, e.g., DPP10 duplication from our
study and the 24 kb partial YWHAE duplication
reported by Gazzellone et al. [10], will also avoid over-
calling of pathogenic CNVs.
In addition to the duplication in patient 6, we identified
two smaller deletions involving PARK2 in two patients not
known to be affected with ASD in our database. One was
found in a patient with GDD, hypotonia and a family history
of ID (lab number AGG0151, arr[GRCh37] 6q26(1627
40393_162865594)x1). The other was found in a patient
with dysmorphism, short stature, and GDD (lab number
AGG0359, arr[GRCh37] 6q26(162687401_162901598)x1)
and was concurrently found to have Russell Silver syndrome
(RSS) due to maternal uniparental disomy 7. While the du-
plication of patient 6 involved exons 2–4, the other two de-
letions overlap exon 2 only. Both deletions and duplications
involving PARK2 have been associated with ASD with vari-
able expressivity and incomplete penetrance [11, 49]. When
considering the pathogenicity, the size of the CNV, exons in-
volved, and whether it was a copy gain or loss should be
considered. It has been suggested that CNVs affecting exons
5–12 result in a more severe phenotype than those affecting
exons 2–4. On the other hand, within exons 2–4, duplica-
tions lead to a more severe phenotype than deletions, due to
greater interference to gene expression [11, 49]. Our find-
ings in this cohort echo the above observations in that the
largest duplication in PARK2 was indeed found in a patient
with ASD, while the smaller deletions involving only exon 2
were identified in non-ASD patients. As we only have one
ASD patient with a CNV involving PARK2, the number is
too small to make any conclusion about the disease causing
nature of this CNV. However, this is in line with the sugges-
tion that PARK2 is a candidate gene and should at least be
considered as a susceptibility locus.
The most important finding in this study is the identifi-
cation of a ~135 kb DPP10 duplication enclosing the 3′
exons of DPP10 as a polymorphism frequently seen in
Chinese population. Given the previous literature on large
case-control studies, we initially concluded that the
DPP10 duplication could be significant and represent an
ASD susceptibility locus. We explored this further by per-
forming a search in our internal CNV database for DPP10
CNVs. To our surprise, we were able to identify 24 such
CNVs (23 duplications and 1 deletion) in our database of
nearly 2000 samples (controls in combination), in contrast
to not a single DPP10 CNV found in nearly 2000 control
subjects from Marshall’s and Girirajan’s studies combined.
We also noted that for most of the DPP10 duplications,
their 3′ and 5′ ends consistently map to the same regions
(Fig. 1). The location of the breakpoints of these CNV in
our database was confirmed by qPCR. We could not iden-
tify any segmental duplication or other signature associ-
ated with homology-based sequence recombination
around these breakpoints. These findings suggest that
these DPP10 duplications likely originate from the same
ancestral event in the Chinese population.
A careful comparison of the prevalence of DPP10 dupli-
cations in our ASD case (1/258) with control (6/653)
showed no statistically significant difference (p = 0.68), sug-
gesting this duplication is not likely to be pathogenic. The
benign nature of this duplication is especially likely as it is a
partial duplication with a breakpoint lying outside the last
exon of the gene. Such postulation is further supported by
findings from our database search including SP2, which
archive normal populations of Chinese ethnicity.
Caution, however, should be exercised when making
broader interpretations regarding the pathogenicity of the
DPP10 in ASD. While the 138 kb duplication in our study,
mapped to the 3′ end of DPP10, might be a benign poly-
morphism, our findings do not exclude the possibility that
other genomic variants involving DPP10 can still have
functional impact on neuronal potassium channel gating,
and hence contribute to the pathogenesis of ASD
and other neurodevelopmental disorders. Further-
more, there is a possibility that the DPP10 duplica-
tion in our study may still confer risk for ASD and
related disorders and should be considered in con-
text. As an example, chromosome 15q11.2 (break-
point_1 to breakpoint_2) deletion is a well-known
CNV that can be found in both patients with autism
or schizophrenia and normal population. Recent
careful neurocognitive profiling has shown that
15q11.2 deletion can confer cognitive deficits with
accompanying MRI changes even in control subjects
[50], illustrating the complexity in interpreting the
contribution of CNVs in neurocognitive phenotypes.
Nonetheless, this finding of CNVs overlapping DPP10
illustrates the importance of using ancestry-matched
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controls and keeping a local internal control database when
characterizing the clinical relevance of rare variants in a
population. This is important in the evaluation of children
with ASD and, perhaps, even more important in prenatal
diagnosis as diagnostic uncertainties may impact on the re-
productive decisions of couples, resulting in unnecessary ter-
mination of pregnancy.
Advantages, limitations, and future directions
There are two main advantages to this study. This is the
first study on the clinical application of aCGH in ASD in-
dividuals in a predominantly Southern Chinese popula-
tion; this is also the first and largest single-center study
reporting DPP10 CNV in normal control subjects, sup-
ported by extensive literature/database search.
Our study has several limitations. The size of our cohort
was small for us to perform comparison of CNV burden
(call rate and length) between patients and controls. Further-
more, only a small percentage of family members consented
for parental aCGH testing and hence, there was insufficient
information on the inheritance, i.e., inherited or de novo.
Our clinical setting and lack of research capacities limited us
to perform further functional studies of our findings, such
as the brain expression pattern of DPP10. Although seven
children born with a prenatal diagnosis of DPP10 duplica-
tion were found to have typical development from routine
child health/development screening, it will be interesting to
prospectively follow-up the full cohort with comprehensive
neurodevelopmental assessment to assess the phenotypic
expressivity and penetrance of this CNV commonly found
in Chinese. It would also be of research value to narrow
down the precise breakpoints of the duplication and clone it
to a simple robust assay for population screening.
Conclusion
We found ten pathogenic and one likely pathogenic
CNV in nine patients of Chinese ancestry, resulting in a
diagnostic yield of 3.5% (9/258). Majority of these CNVs
did not overlap with those previously reported to be im-
plicated in ASD (22q11.2, 1q21, 5q15.2 etc.). We also il-
lustrated that the DPP10 duplication mapped to the 3′
end is likely a benign CNV polymorphism enriched in
Southern Chinese with a population frequency of ~1%,
despite previous reports of its role in ASD. Hence cau-
tion should be taken when making interpretations of
aCGH findings, and ancestry-matched controls should
be used to accurately delineate CNV pathogenicity.
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